<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433924</url>
  </required_header>
  <id_info>
    <org_study_id>D9012R00001</org_study_id>
    <nct_id>NCT03433924</nct_id>
  </id_info>
  <brief_title>An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.</brief_title>
  <acronym>POLARIS</acronym>
  <official_title>An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation of Initial Treatment Pattern and Overall Survival in the Chinese Muscle Invasive Urothelial Bladder Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Primary Objective of this observational study is to investigate the prevalence of high&#xD;
      PD-L1 expression in Chinese MIUBC patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this observational study is:&#xD;
&#xD;
      •To investigate the prevalence of high PD-L1 expression in Chinese MIUBC patients. High PD-L1&#xD;
      expression is defined as ≥25% tumor cell membrane positivity for PD-L1 at any intensity above&#xD;
      background staining as noted on the corresponding negative control OR ≥25% tumor associated&#xD;
      immune cell positivity for PD-L1 at any intensity above background staining as noted on the&#xD;
      corresponding negative control.&#xD;
&#xD;
      Note: PD-L1 High (&gt;=25% tumor cell membrane positivity for PD-L1 or 1) IF IC area &gt;1%: &gt;=25%&#xD;
      tumor associated immune cell positivity for PD-L1; 2) If IC area=1%: 100% tumor associated&#xD;
      immune cell positivity for PD-L1). PD-L1 Low if criteria not met for PD-L1 High.&#xD;
&#xD;
      The second objectives of this observational study are:&#xD;
&#xD;
        -  To investigate the PD-L1 expression profile in TC or IC in Chinese MIUBC patients.&#xD;
&#xD;
        -  To assess the concordance of PD-L1 testing results generated from the hospital labs with&#xD;
           those from the central lab.&#xD;
&#xD;
        -  To observe the initial treatment pattern for MIUBC patients in usual clinical practice&#xD;
           in China.&#xD;
&#xD;
        -  To observe 2-year OS of the Chinese MIUBC patients.&#xD;
&#xD;
      The exploratory objectives of this observational study are:&#xD;
&#xD;
        -  To explore the relationship between the demographic characteristics and expression of&#xD;
           PD-L1 and other exploratory biomarkers including immune cell (IC) subset CD8+ T cells&#xD;
           and tumor mutation burden (TMB).&#xD;
&#xD;
        -  To explore the relationship between OS and the demographic characteristics as well as&#xD;
           the expression of biomarkers.&#xD;
&#xD;
        -  To explore the relationship between PD-L1 and TMB, PD-L1 and CD8 positive T cell&#xD;
           respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Anticipated">May 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 29, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the prevalence of High PD-L1 expression in the MIUBC patients</measure>
    <time_frame>Tumor tissue samples should be acquired within 60 days before the enrollment and available for testing.</time_frame>
    <description>Tumor tissue will be collected from all eligible patients who sign the ICF. Samples will be tested for PD-L1 expression status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with different PD-L1 expression level</measure>
    <time_frame>Tumor tissue samples should be acquired within 60 days before the enrollment and available for testing.</time_frame>
    <description>Proportion of patients with different PD-L1 expression level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1 testing concordance between central lab and hospital labs</measure>
    <time_frame>Tumor tissue samples should be acquired within 60 days before the enrollment and available for testing.</time_frame>
    <description>PD-L1 testing concordance between central lab and hospital labs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution percent of different treatment approaches</measure>
    <time_frame>enrollment visit</time_frame>
    <description>Distribution percent of different treatment approaches</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year OS</measure>
    <time_frame>From enrollment to OS, up to 2 years</time_frame>
    <description>follow up for OS up to 2 years from the baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The prevalence of PD-L1 expression by subgroups</measure>
    <time_frame>enrollment visit</time_frame>
    <description>The prevalence of PD-L1 expression by subgroups according to age, gender, primary tumor site, metastatic disease, at baseline, and prior tobacco use, etc</description>
  </other_outcome>
  <other_outcome>
    <measure>OS by subgroups</measure>
    <time_frame>from enrollment to OS, up to 2 years</time_frame>
    <description>OS by subgroups according to age, gender, primary tumor site, metastatic disease at baseline and the PD-L1 expression of high and low/negative as well as other biomarkers, etc. Simple correlation coefficients among biomarkers including PD-L1 with TMB, PD-L1 with CD8+ T cell, PD-L1+ IC with CD8+ T cell.</description>
  </other_outcome>
  <other_outcome>
    <measure>Simple correlation coefficients among biomarkers</measure>
    <time_frame>enrollment visit</time_frame>
    <description>Simple correlation coefficients among biomarkers including PD-L1 with TMB, PD-L1 with CD8+ T cell, PD-L1 positive IC with CD8+ T cell.</description>
  </other_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Urinary Bladder Cancer</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      the study will collect sections for certain testing following the priority: PD-L1 (3&#xD;
      sections) &gt; CD8 (2 sections) &gt; TMB (6 sections). The minimal required sections number is 3,&#xD;
      specially for PD-L1 testing.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a new diagnosis of MIUBC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years at the time of screening.&#xD;
&#xD;
          -  Be able and willing to sign the informed consent form (ICF);&#xD;
&#xD;
          -  Patients with histologically or cytologically documented, muscle invasive urothelial&#xD;
             carcinoma (ie., T2 toT4, any N, any M) of Bladder, who have not been previously&#xD;
             treated with any systemic chemotherapy, radiotherapy, investigational product, or&#xD;
             biologic therapy for cancer treatment.&#xD;
&#xD;
          -  For PD-L1 testing by IHC assay, all patients must be able to provide a newly acquired&#xD;
             tumor sample within 60 days before enrollment by cystectomy, transurethral resection&#xD;
             or biopsy. Samples with limited tumor content and fine needle aspirate specimens are&#xD;
             not acceptable. Specimens from metastatic bone lesions are typically unacceptable&#xD;
             unless there is a significant soft tissue component.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior acquiring tissuetumor samples exposure to immune-mediated therapy (including&#xD;
             Bacillus Calmette Guerin), including but not limited to, any anti-CTLA-4, anti-PD-1,&#xD;
             anti-PD-L1, or anti-PD-L2 antibodies, including therapeutic anticancer vaccines.&#xD;
&#xD;
          -  Any concurrent chemotherapy, investigational product, or biologic therapy for cancer&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liqun ZHOU, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou</city>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jinan</city>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <zip>2100008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <zip>CN-430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xiamen</city>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Chinese Laws and Regulations don't allow</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

